返回 
加入收藏
羧基麦芽糖铁治疗中国缺铁性贫血成人患者的成本-效果分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 羧基麦芽糖铁治疗中国缺铁性贫血成人患者的成本-效果分析 |
| TITLE： | Cost-effectiveness analysis of ferric carboxymaltose for treating iron deficiency anemia in adult Chinese patients |
| 摘要： | 目的 评价羧基麦芽糖铁注射液治疗中国缺铁性贫血成人患者的经济性。方法从中国卫生体系视角出发，基于一项羧基麦芽糖铁中国Ⅲ期临床试验（NCT03591406）构建分区生存模型，模拟羧基麦芽糖铁和蔗糖铁治疗缺铁性贫血患者的治疗过程及转归，研究时限为1年。计算两种治疗方案的总成本和质量调整生命年（QALYs），并计算增量成本-效果比；对治疗8周之后到研究时限1年之间的疗效参数进行不同假设，基于中国卫生体系和全社会视角进行情境分析，并进行敏感性分析。结果基础分析结果显示，与蔗糖铁相比，羧基麦芽糖铁方案的增量效果为0.007QALYs，费用可节省1038元，健康产出更高而总成本更低，属于绝对优势方案；情境分析和单因素敏感性分析结果与基础分析一致。概率敏感性分析结果显示，分别以1、2、3倍2022年中国人均国内生产总值为阈值时，羧基麦芽糖铁方案具有经济性的概率为88.2%、94.5%、97.6%。结论对于中国缺铁性贫血成人患者来说，与蔗糖铁疗法相比，羧基麦芽糖铁是一种更具经济性的治疗方案。 |
| ABSTRACT： | OBJECTIVE To evaluate the cost-effectiveness of Ferric carboxymaltose injection in the treatment of iron deficiency anemia in adult Chinese patients. METHODS From the perspective of China’s health system， the partitioned survival model was constructed to simulate the treatment process and outcome of patients with iron deficiency anemia using ferric carboxymaltose and iron sucrose based on the ferric carboxymaltose phase Ⅲ clinical trial in China （NCT03591406）. The study period was 1 year. Total costs and quality-adjusted life years （QALYs） were calculated for both treatment regimens， and incremental cost-effectiveness ratios were calculated. Scenario analysis was performed with different assumptions for efficacy parameters between 9th week and the end of 1 year， and from the perspective of China’s health system and the entire society. The sensitivity analysis was also performed. RESULTS In the basic analysis， compared with iron sucrose， incremental effectiveness of ferric carboxymaltose therapy was 0.007 QALYs， with an additional savings of 1 038 yuan per patient. Ferric carboxymaltose therapy was more effective and less costly， presenting an absolute advantage. The results of the scenario analysis and single-factor sensitivity analysis were consistent with the basic analysis. Probability sensitivity analysis showed that when the willingness-to-pay threshold was 1， 2， 3 times gross domestic product per capita in 2022， the probability of ferric carboxymaltose with a cost- effectiveness advantage was 88.2%，94.5% and 97.6%，respectively. CONCLUSIONS For Chinese adults with iron deficiency anemia， ferric carboxymaltose is a cost-effective treatment for iron deficiency anemia， compared with iron sucrose. |
| 期刊： | 2023年第34卷第22期 |
| 作者： | 孙文韬；庄铃香；马爱霞 |
| AUTHORS： | SUN Wentao，ZHUANG Lingxiang，MA Aixia |
| 关键字： | 羧基麦芽糖铁注射液；缺铁性贫血；成本-效果分析；分区生存模型 |
| KEYWORDS： | Ferric carboxymaltose injection； iron deficiency anemia； cost-effectiveness analysis； partitioned survival model |
| 阅读数： | 49 次 |
| 本月下载数： | 7 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
